SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
SCYNEXIS, Inc. (NASDAQ: SCYX) has scheduled a conference call for November 9, 2022, at 8:30 a.m. EDT to discuss its third-quarter financial results for the period ending September 30, 2022. The company, focused on developing innovative medicines for drug-resistant infections, has received FDA approval for its antifungal product, BREXAFEMME, and filed a supplemental New Drug Application for expanded indications, with a target FDA action date of November 30, 2022. The call will also provide corporate updates and insights into ongoing clinical trials.
- FDA approval of BREXAFEMME enhances market position.
- Ongoing clinical trials could lead to new treatment opportunities.
- No specific financial results or guidance provided ahead of the call.
JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2022.
Conference call and webcast details:
Investors (domestic): (844) 826-3033
Investors (international): (412) 317-5185
Webcast: Link
Conference ID: 10172836
A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand BREXAFEMME’s labelling to include the prevention of recurrent vulvovaginal candidiasis, and the FDA assigned a target PDUFA action date of November 30, 2022 for this additional indication. In addition, late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
Media Relations
Debbie Etchison
SCYNEXIS
debbie.etchison@scynexis.com
FAQ
When is SCYNEXIS's upcoming conference call?
What financial results will SCYNEXIS discuss during the call?
What is the FDA action date for SCYNEXIS's supplemental drug application?
What indications is SCYNEXIS aiming for with BREXAFEMME?
